Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs BGNE

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:BGNE)

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Business Wire March 14, 2024

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Business Wire March 13, 2024

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

Business Wire March 7, 2024

BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

Business Wire March 6, 2024

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Business Wire February 29, 2024

BeiGene to Present at Upcoming Investor Conferences

Business Wire February 28, 2024

BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

Business Wire February 27, 2024

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Business Wire February 26, 2024

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Business Wire February 26, 2024

Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Canada NewsWire February 7, 2024

Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

Canada NewsWire January 31, 2024

BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors

Business Wire January 23, 2024

FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)

Business Wire December 22, 2023

BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire December 21, 2023

BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023

Business Wire November 29, 2023

BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023

Business Wire November 28, 2023

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

Business Wire November 21, 2023

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Business Wire November 17, 2023

BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates

Business Wire November 9, 2023

BeiGene to Present at the Jefferies London Healthcare Conference

Business Wire November 8, 2023